UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Evolving Paradigms in the Systemic Treatment of Advanced Gallbladder Cancer: Updates in Year 2022

Cancers, 2022-02, Vol.14 (5), p.1249

2022

Volltextzugriff (PDF)

A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer

Cancer medicine (Malden, MA), 2019-09, Vol.8 (11), p.5148-5157

2019

Volltextzugriff (PDF)

The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma

Cancers, 2023-10, Vol.15 (19), p.4875

2023

Volltextzugriff (PDF)

Pancreatic tail cancer in the setting of pancreatitis with a review of the literature: A case report

Clinical case reports, 2023-10, Vol.11 (10), p.e8023-n/a

2023

Volltextzugriff (PDF)

Acquired resistance to immunotherapy in MMR-D pancreatic cancer

Journal for immunotherapy of cancer, 2018-11, Vol.6 (1), p.127-6, Article 127

2018

Volltextzugriff (PDF)

Intracystic Papillary Carcinoma of the Breast in a Male Patient

Rare tumors, 2016-03, Vol.8 (1), p.6050-10

2016

Volltextzugriff (PDF)

Efficacy of adjuvant fluoropyrimidine with or without oxaliplatin therapy in older adults with mismatch repair deficient stage III colorectal cancer

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.112-112

2023

Volltextzugriff (PDF)

Association of FGFR2 structural alterations in intrahepatic cholangiocarcinomas with female gender and younger age

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.537-537

2024

Volltextzugriff (PDF)

Bleeding and thrombotic events in patients with colorectal cancer treated with bevacizumab and receiving novel oral anticoagulants and antiplatelet medications

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.104-104

2023

Volltextzugriff (PDF)

Characterizing KRAS allele variants within biliary tract cancers

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4088-4088

2023

Volltextzugriff (PDF)

Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota

Proceedings of the National Academy of Sciences - PNAS, 2022-06, Vol.119 (26), p.e2200348119

2022

Volltextzugriff (PDF)

SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAF V600E metastatic and/or unresectable colorectal cancer

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.TPS234-TPS234

2024

Volltextzugriff (PDF)

Clinician utilization of a plasma-only, multiomic minimal residual disease (MRD) assay in 2,000 consecutive patients with colorectal cancer (CRC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e15586-e15586

2022

Volltextzugriff (PDF)

Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAF V600E metastatic and/or unresectable colorectal cancer: SWOG S2107

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.TPS265-TPS265

2023

Volltextzugriff (PDF)

A phase 1/2 study of the TBL1 inhibitor, tegavivint (BC2059), in patients (pts) with advanced hepatocellular carcinoma (aHCC) with β-catenin activating mutations

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.TPS4192-TPS4192

2024

Volltextzugriff (PDF)

Plasma growth hormone as a prognostic biomarker to durvalumab and tremelimumab in patients with advanced hepatocellular carcinoma

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e16161-e16161

2024

Volltextzugriff (PDF)

Dysphagia and Neck Swelling in a Case of Undiagnosed Lhermitte-Duclos Disease and Cowden Syndrome

Case reports in oncological medicine, 2015-01, Vol.2015 (2015), p.1-4

2015

Volltextzugriff (PDF)

Serologic, radiographic, and tissue-based markers associated with major pathologic response after treatment with neoadjuvant immunotherapy in patients with resectable hepatocellular carcinoma

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.561-561

2024

Volltextzugriff (PDF)

A phase 2/3 randomized study of CTX-009 combination in 2L biliary tract cancer: COMPANION-002

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.TPS587-TPS587

2024

Volltextzugriff (PDF)

Characterization of outcomes and genomic alterations (GA) in combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA)

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.458-458

2024

Volltextzugriff (PDF)

Characterizing outcomes of ERBB2-amplified biliary tract cancer

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.492-492

2024

Volltextzugriff (PDF)

Phase I trial of CA-4948, an IRAK4 inhibitor, in combination with FOLFOX/PD-1 inhibitor +/- trastuzumab for untreated unresectable gastric and esophageal cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS4168-TPS4168

2022

Volltextzugriff (PDF)

Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma

Oncology, 2023-10, Vol.101 (11), p.730-737

2023

Volltextzugriff (PDF)

KRAS Allelic Variants in Biliary Tract Cancers

JAMA network open, 2024-05, Vol.7 (5), p.e249840-e249840

2024

Volltextzugriff (PDF)

Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNivo) +/- ipilimumab (CaboNivoIpi)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.4555-4555

2019

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(32)
Berichte
(1)

Sprache

Englisch
(33)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(30)
Journals@Ovid Full Text
(19)
Ingenta
(18)
NUS Single-Journal Subscriptions
(18)
IngentaConnect Journals
(16)
MEDLINE
(5)
SAGE Journals
(3)
Wiley Online Library - AutoHoldings Journals
(2)
JSTOR
(1)
BMJ_英国医学会期刊
(1)
SpringerLink_现刊
(1)
Taylor & Francis Journals
(1)

7 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Evolving Paradigms in the Systemic Treatment of Advanced Gallbladder Cancer: Updates in Year 2022

A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer

The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma

Pancreatic tail cancer in the setting of pancreatitis with a review of the literature: A case report

Acquired resistance to immunotherapy in MMR-D pancreatic cancer

Intracystic Papillary Carcinoma of the Breast in a Male Patient

Efficacy of adjuvant fluoropyrimidine with or without oxaliplatin therapy in older adults with mismatch repair deficient stage III colorectal cancer

Association of FGFR2 structural alterations in intrahepatic cholangiocarcinomas with female gender and younger age

Bleeding and thrombotic events in patients with colorectal cancer treated with bevacizumab and receiving novel oral anticoagulants and antiplatelet medications

Characterizing KRAS allele variants within biliary tract cancers

Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota

SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAF V600E metastatic and/or unresectable colorectal cancer

Clinician utilization of a plasma-only, multiomic minimal residual disease (MRD) assay in 2,000 consecutive patients with colorectal cancer (CRC)

Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAF V600E metastatic and/or unresectable colorectal cancer: SWOG S2107

A phase 1/2 study of the TBL1 inhibitor, tegavivint (BC2059), in patients (pts) with advanced hepatocellular carcinoma (aHCC) with β-catenin activating mutations

Plasma growth hormone as a prognostic biomarker to durvalumab and tremelimumab in patients with advanced hepatocellular carcinoma

Dysphagia and Neck Swelling in a Case of Undiagnosed Lhermitte-Duclos Disease and Cowden Syndrome

Serologic, radiographic, and tissue-based markers associated with major pathologic response after treatment with neoadjuvant immunotherapy in patients with resectable hepatocellular carcinoma

A phase 2/3 randomized study of CTX-009 combination in 2L biliary tract cancer: COMPANION-002

Characterization of outcomes and genomic alterations (GA) in combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA)

Characterizing outcomes of ERBB2-amplified biliary tract cancer

Phase I trial of CA-4948, an IRAK4 inhibitor, in combination with FOLFOX/PD-1 inhibitor +/- trastuzumab for untreated unresectable gastric and esophageal cancer

Clinical and Prognostic Biomarker Value of Blood-Circulating Inflammatory Cytokines in Hepatocellular Carcinoma

KRAS Allelic Variants in Biliary Tract Cancers

Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNivo) +/- ipilimumab (CaboNivoIpi)

Suchergebnisse filtern